Miyashita Naoyuki, Fukano Hiroshi, Yoshida Koichiro, Niki Yoshihito, Matsushima Toshiharu
Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama 701-0192, Japan.
J Antimicrob Chemother. 2003 Sep;52(3):497-9. doi: 10.1093/jac/dkg371. Epub 2003 Aug 13.
To investigate the in vitro activity of cethromycin, a new ketolide, against Chlamydia pneumoniae.
The in vitro activity of cethromycin against 20 isolates of C. pneumoniae was compared with the activities of telithromycin, erythromycin A, azithromycin and clarithromycin against those isolates.
The MIC at which 90% of the isolates were inhibited and the minimal chlamydiacidal concentration at which 90% of the isolates were killed by cethromycin were both 0.016 mg/L (range 0.016-0.031 mg/L). Cethromycin was the most active antibiotic tested in this study.
Our results appear to indicate that cethromycin is an effective antibiotic that should play some role in the treatment of respiratory tract infections caused by C. pneumoniae.
研究新型酮内酯类药物赛托霉素对肺炎衣原体的体外活性。
比较赛托霉素对20株肺炎衣原体分离株的体外活性与泰利霉素、红霉素A、阿奇霉素和克拉霉素对这些分离株的活性。
赛托霉素抑制90%分离株的最低抑菌浓度（MIC）和杀灭90%分离株的最低杀衣原体浓度均为0.016mg/L（范围为0.016 - 0.031mg/L）。赛托霉素是本研究中活性最强的抗生素。
我们的结果似乎表明，赛托霉素是一种有效的抗生素，在治疗由肺炎衣原体引起的呼吸道感染中应发挥一定作用。
